JP2015536950A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015536950A5 JP2015536950A5 JP2015540834A JP2015540834A JP2015536950A5 JP 2015536950 A5 JP2015536950 A5 JP 2015536950A5 JP 2015540834 A JP2015540834 A JP 2015540834A JP 2015540834 A JP2015540834 A JP 2015540834A JP 2015536950 A5 JP2015536950 A5 JP 2015536950A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- cell lymphoma
- lymphoma
- ibrutinib
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261722107P | 2012-11-02 | 2012-11-02 | |
| US61/722,107 | 2012-11-02 | ||
| US201361785868P | 2013-03-14 | 2013-03-14 | |
| US61/785,868 | 2013-03-14 | ||
| PCT/US2013/068132 WO2014071231A1 (en) | 2012-11-02 | 2013-11-01 | Tec family kinase inhibitor adjuvant therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018179447A Division JP2019031506A (ja) | 2012-11-02 | 2018-09-25 | Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015536950A JP2015536950A (ja) | 2015-12-24 |
| JP2015536950A5 true JP2015536950A5 (enExample) | 2016-12-22 |
Family
ID=50628113
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540834A Pending JP2015536950A (ja) | 2012-11-02 | 2013-11-01 | Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法 |
| JP2018179447A Ceased JP2019031506A (ja) | 2012-11-02 | 2018-09-25 | Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法 |
| JP2020120047A Pending JP2020183413A (ja) | 2012-11-02 | 2020-07-13 | Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018179447A Ceased JP2019031506A (ja) | 2012-11-02 | 2018-09-25 | Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法 |
| JP2020120047A Pending JP2020183413A (ja) | 2012-11-02 | 2020-07-13 | Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9717731B2 (enExample) |
| EP (1) | EP2914263A4 (enExample) |
| JP (3) | JP2015536950A (enExample) |
| KR (1) | KR20150080592A (enExample) |
| CN (2) | CN111329989A (enExample) |
| AU (3) | AU2013337663A1 (enExample) |
| BR (1) | BR112015010059A2 (enExample) |
| CA (1) | CA2890111A1 (enExample) |
| CL (1) | CL2015001147A1 (enExample) |
| CR (1) | CR20150242A (enExample) |
| DO (1) | DOP2015000098A (enExample) |
| EA (1) | EA201590822A1 (enExample) |
| HK (1) | HK1214508A1 (enExample) |
| IL (1) | IL238548A0 (enExample) |
| MX (2) | MX2015005633A (enExample) |
| NI (1) | NI201500062A (enExample) |
| PE (1) | PE20151604A1 (enExample) |
| PH (1) | PH12015500985A1 (enExample) |
| SG (1) | SG11201503459SA (enExample) |
| TN (1) | TN2015000170A1 (enExample) |
| TW (1) | TW201427664A (enExample) |
| WO (1) | WO2014071231A1 (enExample) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| SG10201510696RA (en) | 2008-06-27 | 2016-01-28 | Celgene Avilomics Res Inc | Heteroaryl compounds and uses thereof |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| JP5918693B2 (ja) | 2009-05-05 | 2016-05-18 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | Ｅｇｆｒ阻害剤及び疾患の治療方法 |
| CA3007787C (en) | 2010-06-03 | 2020-03-10 | Pharmacyclics Llc | The use of inhibitors of bruton's tyrosine kinase (btk) |
| MY160734A (en) | 2010-08-10 | 2017-03-15 | Celgene Avilomics Res Inc | Besylate salt of a btk inhibitor |
| DK2632927T3 (en) | 2010-10-26 | 2016-04-11 | Mars Inc | Boronates AS ARGINSASEINHIBITORER |
| NZ710636A (en) | 2010-11-01 | 2017-02-24 | Celgene Avilomics Res Inc | Heterocyclic compounds and uses thereof |
| WO2012061303A1 (en) | 2010-11-01 | 2012-05-10 | Avila Therapeutics, Inc. | Heteroaryl compounds and uses thereof |
| WO2012064706A1 (en) | 2010-11-10 | 2012-05-18 | Avila Therapeutics, Inc. | Mutant-selective egfr inhibitors and uses thereof |
| CA2853498A1 (en) | 2011-10-28 | 2013-05-02 | Celgene Avilomics Research, Inc. | Methods of treating a bruton's tyrosine kinase disease or disorder |
| BR112014022789B1 (pt) | 2012-03-15 | 2022-04-19 | Celgene Car Llc | Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo |
| SMT201800571T1 (it) | 2012-03-15 | 2019-01-11 | Celgene Car Llc | Sali di un inibitore di chinasi del recettore del fattore di crescita dell’epidermide |
| CA2879570A1 (en) | 2012-07-24 | 2014-01-30 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| PE20151604A1 (es) | 2012-11-02 | 2015-11-04 | Pharmacyclics Llc | Terapia adyuvante con inhibidores de quinasa de la familia tec |
| US9126950B2 (en) | 2012-12-21 | 2015-09-08 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| US9561228B2 (en) | 2013-02-08 | 2017-02-07 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
| CA2938626A1 (en) | 2013-07-26 | 2015-01-29 | John Rothman | Compositions to improve the therapeutic benefit of bisantrene |
| TWI649081B (zh) * | 2013-08-02 | 2019-02-01 | 製藥公司 | 治療固態腫瘤之方法 |
| US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
| WO2015061752A1 (en) * | 2013-10-25 | 2015-04-30 | Pharmacyclics, Inc. | Treatment using bruton's tyrosine kinase inhibitors and immunotherapy |
| WO2015084892A1 (en) * | 2013-12-02 | 2015-06-11 | Cornell University | Methods for treating b cell proliferative disorders |
| US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
| EP3119910A4 (en) | 2014-03-20 | 2018-02-21 | Pharmacyclics LLC | Phospholipase c gamma 2 and resistance associated mutations |
| US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| WO2015187848A1 (en) * | 2014-06-04 | 2015-12-10 | Sampath Deepa | Hdac inhibitor and btk inhibitor combinations |
| WO2015192081A1 (en) * | 2014-06-13 | 2015-12-17 | Byrd, John C. | Biomarker for predicting response of cll to treatment with a btk inhibitor |
| WO2016010961A1 (en) * | 2014-07-15 | 2016-01-21 | Abbvie Inc. | Enzyme occupancy assay |
| EP3171897A4 (en) | 2014-07-25 | 2018-03-21 | Northeastern University | Biopolymer-nanoparticle composite implant for tumor cell tracking |
| US10005760B2 (en) | 2014-08-13 | 2018-06-26 | Celgene Car Llc | Forms and compositions of an ERK inhibitor |
| WO2016044774A1 (en) * | 2014-09-18 | 2016-03-24 | Pharmacyclics Llc | Dendritic cell based vaccine with bruton's tyrosine kinase inhibitor |
| JP2017536403A (ja) * | 2014-12-04 | 2017-12-07 | アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | デルタ肝炎ウイルス感染の治療 |
| US20180098972A1 (en) | 2015-01-26 | 2018-04-12 | Children's Medical Center Corporation | Treatment of infectious diseases |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11512289B2 (en) | 2015-02-18 | 2022-11-29 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| WO2016138542A1 (en) * | 2015-02-28 | 2016-09-01 | Cyprus Therapeutics, Inc. | Methods for inhibiting tumors and drug resistance |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibitor |
| HK1251165A1 (en) | 2015-04-13 | 2019-01-25 | Daiichi Sankyo Company, Limited | Treatment method combining mdm2 inhibitor and btk inhibitor |
| EP4140492A1 (en) | 2015-04-21 | 2023-03-01 | Enlivex Therapeutics Rdo Ltd | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| HUE054068T2 (hu) | 2015-04-21 | 2021-08-30 | Eiger Biopharmaceuticals Inc | Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények |
| CN107683139A (zh) | 2015-05-29 | 2018-02-09 | 博尔托拉制药公司 | 用于治疗b细胞恶性肿瘤的赛度替尼 |
| US11554138B2 (en) | 2015-07-16 | 2023-01-17 | The University Of Hong Kong | Bismuth(III) complexes as adjuvants in the treatment of cancer using platinum-based chemotherapy |
| JP2018522028A (ja) * | 2015-07-31 | 2018-08-09 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ阻害剤の組み合わせ及びそれらの使用 |
| ES2913119T3 (es) | 2015-08-12 | 2022-05-31 | Portola Pharm Inc | Cerdulatinib para tratar mieloma |
| SG11201802961PA (en) * | 2015-10-30 | 2018-05-30 | Calithera Biosciences Inc | Compositions and methods for inhibiting arginase activity |
| CN108367006B (zh) | 2015-12-04 | 2021-12-31 | 博尔托拉制药公司 | 用于治疗血液癌症的赛度替尼 |
| JP6884155B2 (ja) | 2016-02-18 | 2021-06-09 | エンリヴェックス セラピューティクス リミテッド | 癌治療のための併用免疫療法及びサイトカイン制御療法 |
| PL3416675T3 (pl) | 2016-02-19 | 2021-10-11 | Eiger Biopharmaceuticals, Inc. | Leczenie zakażenia wirusem zapalenia wątroby typu delta za pomocą interferonu lambda |
| EP3478273A1 (en) | 2016-06-29 | 2019-05-08 | Principia Biopharma Inc. | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| EP3318276A1 (en) | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers |
| CN106405086A (zh) * | 2016-09-21 | 2017-02-15 | 四川大学华西医院 | 一种肺癌筛查试剂盒 |
| US20190298772A1 (en) | 2016-11-03 | 2019-10-03 | Juno Therapeutics, Inc. | Combination therapy of a t cell-based therapy and a btk inhibitor |
| EP3548046A2 (en) | 2016-12-03 | 2019-10-09 | Juno Therapeutics, Inc. | Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors |
| NZ754364A (en) | 2016-12-22 | 2023-04-28 | Calithera Biosciences Inc | Compositions and methods for inhibiting arginase activity |
| CN108732280B (zh) * | 2017-04-18 | 2022-07-08 | 广东东阳光药业有限公司 | 一种分离检测盐酸达卡他韦及其光学异构体的方法 |
| WO2019014684A1 (en) * | 2017-07-14 | 2019-01-17 | Ohio State Innovation Foundation | EXPANSION OF IMMUNE CELLS WITH INTERLEUKIN-INDUCIBLE T CELL KINASE-INHIBITING COMPOUNDS |
| EP3688007B1 (en) | 2017-09-27 | 2024-07-31 | The University of York | Bioconjugation of polypeptides |
| CZ2017787A3 (cs) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
| EP3787751A1 (en) | 2018-05-03 | 2021-03-10 | Juno Therapeutics, Inc. | Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor |
| WO2019213606A2 (en) | 2018-05-04 | 2019-11-07 | Portola Pharmaceuticals, Inc. | Solid forms of cerdulatinib |
| CN111110685A (zh) * | 2018-10-31 | 2020-05-08 | 正大天晴药业集团股份有限公司 | 一种含伊布替尼的药物组合物及其应用 |
| US20220339156A1 (en) * | 2019-09-09 | 2022-10-27 | The Children's Hospital Of Philadelphia | Compositions and methods for treatment of disorders associated with clec16a dysfunction or loss |
| EP4045051A1 (en) | 2019-10-14 | 2022-08-24 | Principia Biopharma Inc. | Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| US20220378025A1 (en) * | 2019-11-11 | 2022-12-01 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric genes |
| PH12022551787A1 (en) | 2020-01-22 | 2024-02-12 | Principia Biopharma Inc | Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| WO2021207716A2 (en) * | 2020-04-10 | 2021-10-14 | Ohio State Innovation Foundation | Methods and composition for treatment of covid-19 illness requiring hospitalization |
| WO2021252494A1 (en) * | 2020-06-08 | 2021-12-16 | Icahn School Of Medicine At Mount Sinai | Use of multi-kinase inhibitors to treat rna virus infections |
| WO2023196278A1 (en) * | 2022-04-05 | 2023-10-12 | Corvus Pharmaceuticals, Inc. | Itk inhibitors for increasing th1 cell activity |
| US20250302954A1 (en) | 2022-05-11 | 2025-10-02 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| WO2025071560A1 (en) * | 2023-09-28 | 2025-04-03 | Rutgers, The State University Of New Jersey | Methods of diagnosing b cell malignancies, detecting b cell malignancy relapse, and treating thereof |
| WO2024206869A2 (en) * | 2023-03-30 | 2024-10-03 | Board Of Regents, The University Of Texas System | Combination of hpk1 inhibitor and axl inhibitor in cancer therapy |
| WO2025085889A1 (en) * | 2023-10-20 | 2025-04-24 | Corvus Pharmaceuticals, Inc. | Interleukin-2-inducible t-cell kinase inhibitors to produce enhanced immune responses |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| EP1240899A3 (en) | 1996-01-23 | 2004-05-19 | Ribapharm, Inc. | Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections |
| EP1302474A1 (en) | 1996-10-16 | 2003-04-16 | Ribapharm, Inc. | Monocyclic L-nucleosides, analogs and uses thereof |
| US7390619B1 (en) | 1998-02-11 | 2008-06-24 | Maxygen, Inc. | Optimization of immunomodulatory properties of genetic vaccines |
| US7087236B1 (en) | 1998-09-01 | 2006-08-08 | Merrion Research I Limited | Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof |
| CA2345722A1 (en) | 1998-09-28 | 2000-04-06 | Albert Edge | Determining resistance to treatment for hepatitis c virus |
| US6824768B2 (en) | 1998-12-18 | 2004-11-30 | Schering Corporation | Ribavirin-pegylated interferon alfa induction HCV combination therapy |
| AR023541A1 (es) | 1999-04-19 | 2002-09-04 | Schering Corp | Terapia de combinacion para vhc |
| EP1227844A2 (en) | 1999-10-29 | 2002-08-07 | Pharmacyclics, Inc. | Compositions for treating atheroma and neoplastic tissue |
| AU2001249120A1 (en) | 2000-03-09 | 2001-09-17 | Schering Corporation | Hiv immune adjuvant therapy |
| US20020039734A1 (en) | 2000-05-18 | 2002-04-04 | Hanrahan Catherine F. | Compositions, kits, and methods for identification and modulation of T helper-1 and T helper-2 cells and diseases associated therewith |
| AU2002213343A1 (en) | 2000-10-18 | 2002-04-29 | Schering Corporation | Ribavirin-pegylated interferon alfa HCV combination therapy |
| US20030103938A1 (en) | 2001-05-09 | 2003-06-05 | Alk-Abello A/S | Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio |
| GB0116249D0 (en) | 2001-07-05 | 2001-08-29 | Imp College Innovations Ltd | Methods |
| KR20050037552A (ko) | 2002-07-15 | 2005-04-22 | 와이어쓰 | Ｔ 헬퍼(ｔｈ) 세포 발생 및 기능을 조절하는 방법 및조성물 |
| JP2006512391A (ja) | 2002-12-30 | 2006-04-13 | スリーエム イノベイティブ プロパティズ カンパニー | 組み合わせ免疫賦活薬 |
| WO2004110245A2 (en) | 2003-05-16 | 2004-12-23 | Intermune, Inc. | Combination therapy for cancer treatment |
| EP1670503A4 (en) | 2003-09-30 | 2008-09-24 | Telethon Inst For Child Health | IMMUNOTHERAPY METHOD |
| WO2007052059A2 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Changing th1/th2 balance in split influenza vaccines with adjuvants |
| WO2007059329A2 (en) | 2005-11-16 | 2007-05-24 | Pharmacyclics, Inc. | Methods and compositions for treating cancer |
| GB0605521D0 (en) | 2006-03-18 | 2006-04-26 | Isis Innovation | Adjuvant |
| CA2666814A1 (en) | 2006-08-21 | 2008-05-29 | United Therapeutics Corporation | Combination therapy for treatment of viral infections |
| EA018573B1 (ru) * | 2006-09-22 | 2013-09-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
| US20120065201A1 (en) | 2007-03-28 | 2012-03-15 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| CN104059143A (zh) | 2007-11-12 | 2014-09-24 | 特罗科隆科学有限公司 | 用于对流行性感冒进行治疗以及诊断的组合物以及方法 |
| GB0805356D0 (en) | 2008-03-25 | 2008-04-30 | Isis Innovation | Vaccine adjuvant composition |
| WO2009140853A1 (en) | 2008-05-23 | 2009-11-26 | The University Of Hong Kong | Combination therapy for the treatment of influenza |
| WO2009149179A2 (en) | 2008-06-03 | 2009-12-10 | Aethlon Medical Inc. | Enhanced antiviral therapy methods and devices |
| JP2012503619A (ja) | 2008-09-26 | 2012-02-09 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｈｃｖ感染に対する抗ウイルス治療のための標的としての宿主細胞キナーゼ |
| SG172227A1 (en) | 2008-12-18 | 2011-07-28 | Hoffmann La Roche | Biomarkers for hcv treatment response |
| EP2396028A2 (en) | 2009-02-12 | 2011-12-21 | Vertex Pharmceuticals Incorporated | Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir |
| AU2010239368A1 (en) | 2009-04-20 | 2011-11-10 | Genentech, Inc. | Adjuvant cancer therapy |
| US8299070B2 (en) | 2009-11-25 | 2012-10-30 | Japan Tobacco Inc. | Indole compounds and pharmaceutical use thereof |
| CA3007787C (en) * | 2010-06-03 | 2020-03-10 | Pharmacyclics Llc | The use of inhibitors of bruton's tyrosine kinase (btk) |
| GB2481611A (en) | 2010-06-30 | 2012-01-04 | Statoil Asa | Test cell for well fluid assessment |
| RU2013127625A (ru) * | 2010-11-18 | 2014-12-27 | Зе Дженерал Хоспитал Корпорейшен | Новые композиции и применения антигипертензивных средств для терапии рака |
| EP2724156B1 (en) | 2011-06-27 | 2017-08-16 | The Jackson Laboratory | Methods and compositions for treatment of cancer and autoimmune disease |
| WO2013036994A1 (en) | 2011-09-16 | 2013-03-21 | Biota Scientific Management Pty Ltd | Compounds for the treatment of hcv |
| WO2013085893A1 (en) | 2011-12-05 | 2013-06-13 | Immunomedics, Inc. | Therapeutic use of anti-cd22 antibodies for inducing trogocytosis |
| EA201492082A1 (ru) * | 2012-06-04 | 2015-03-31 | Фармасайкликс, Инк. | Кристаллические формы ингибитора тирозинкиназы брутона |
| PE20151604A1 (es) | 2012-11-02 | 2015-11-04 | Pharmacyclics Llc | Terapia adyuvante con inhibidores de quinasa de la familia tec |
-
2013
- 2013-11-01 PE PE2015000592A patent/PE20151604A1/es not_active Application Discontinuation
- 2013-11-01 HK HK16102454.7A patent/HK1214508A1/zh unknown
- 2013-11-01 AU AU2013337663A patent/AU2013337663A1/en not_active Abandoned
- 2013-11-01 TW TW102139881A patent/TW201427664A/zh unknown
- 2013-11-01 WO PCT/US2013/068132 patent/WO2014071231A1/en not_active Ceased
- 2013-11-01 CN CN202010271248.7A patent/CN111329989A/zh active Pending
- 2013-11-01 BR BR112015010059A patent/BR112015010059A2/pt not_active Application Discontinuation
- 2013-11-01 US US14/070,420 patent/US9717731B2/en active Active
- 2013-11-01 CA CA2890111A patent/CA2890111A1/en not_active Abandoned
- 2013-11-01 EA EA201590822A patent/EA201590822A1/ru unknown
- 2013-11-01 SG SG11201503459SA patent/SG11201503459SA/en unknown
- 2013-11-01 MX MX2015005633A patent/MX2015005633A/es unknown
- 2013-11-01 KR KR1020157014129A patent/KR20150080592A/ko not_active Withdrawn
- 2013-11-01 CN CN201380065469.7A patent/CN104994858A/zh active Pending
- 2013-11-01 EP EP13850097.0A patent/EP2914263A4/en not_active Withdrawn
- 2013-11-01 JP JP2015540834A patent/JP2015536950A/ja active Pending
-
2014
- 2014-03-05 US US14/198,559 patent/US20140371241A1/en not_active Abandoned
-
2015
- 2015-04-30 CL CL2015001147A patent/CL2015001147A1/es unknown
- 2015-04-30 DO DO2015000098A patent/DOP2015000098A/es unknown
- 2015-04-30 NI NI201500062A patent/NI201500062A/es unknown
- 2015-04-30 IL IL238548A patent/IL238548A0/en unknown
- 2015-05-04 TN TNP2015000170A patent/TN2015000170A1/fr unknown
- 2015-05-04 MX MX2021003018A patent/MX2021003018A/es unknown
- 2015-05-04 PH PH12015500985A patent/PH12015500985A1/en unknown
- 2015-05-08 CR CR20150242A patent/CR20150242A/es unknown
-
2017
- 2017-07-14 US US15/650,830 patent/US20180071293A1/en not_active Abandoned
-
2018
- 2018-09-21 AU AU2018233032A patent/AU2018233032B2/en not_active Ceased
- 2018-09-25 JP JP2018179447A patent/JP2019031506A/ja not_active Ceased
-
2019
- 2019-05-21 US US16/418,590 patent/US20200147084A1/en not_active Abandoned
-
2020
- 2020-07-13 JP JP2020120047A patent/JP2020183413A/ja active Pending
- 2020-08-21 AU AU2020220205A patent/AU2020220205A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015536950A5 (enExample) | ||
| PH12016500575A1 (en) | Inhibitors of bruton`s tyrosine kinase | |
| MX2014009219A (es) | Compuestos de purinona como inhibidores de quinasas. | |
| CN112888458A (zh) | Cldn18的抗体和化疗药物的联合治疗 | |
| PH12015501067A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
| JP2016506908A5 (enExample) | ||
| PH12015500940A1 (en) | Bruton`s tyrosine kinase inhibitors | |
| JP2018508469A5 (enExample) | ||
| NZ593343A (en) | Combination cancer treatment conprising Abraxane and an inflamatory inhibitor | |
| EP3686200A3 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| CN106659757A8 (zh) | 白介素2的超级激动剂、部分激动剂和拮抗剂 | |
| WO2016196776A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| JP2013527232A5 (enExample) | ||
| JP2011079858A5 (enExample) | ||
| NZ707377A (en) | Combination therapy methods for treating proliferative diseases | |
| WO2014144130A3 (en) | Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof | |
| CL2014002557A1 (es) | Compuestos bicíclicos de pirazinona; procedimiento de preparacion; composicion farmaceutica; kit; y uso en el tratamiento y/o prevencion de enfermedades cardiovasculares, cancer, entre otras. | |
| WO2014165412A3 (en) | Methods and compositions for treating cancers having acquired resistance to chemotherapeutic and targeted drugs using carboxyamidotriazole orotate | |
| JP2006500346A5 (enExample) | ||
| WO2009140675A3 (en) | Combination therapy with pm00104 and another antitumor agent | |
| RU2015152785A (ru) | Лечение злокачественной опухоли налтрексоном | |
| EP4410373A3 (en) | Nucleic acid simultaneously inhibiting expression of mtor gene and stat3 gene | |
| CN110062628A (zh) | 一种瑞卡帕布口服缓控释药物组合物及其用途 | |
| WO2018033941A3 (en) | Pharmaceutical compositions of ibrutinib | |
| WO2008053484A3 (en) | Preparation of heavy metal-containing nano-liposomes and their uses in medical therapy |